A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

Inclusion Criteria:

• Male or female diagnosed with type 2 diabetes
• Age at least 50 years at screening and presence of cardiovascular disease, or age atleast 60 years at screening and presence of at least one cardiovascular risk factor

Exclusion Criteria:

• Current or previous (within 90 days prior to screening) treatment with any GLP-1 (glucagon-like peptide-1) receptor agonist, DPP-4 (dipeptidyl peptidase-4) inhibitoror pramlintide
• Family or personal history of multiple endocrine neoplasia type 2 (MEN 2) or medullarythyroid carcinoma (MTC)
• History of pancreatitis (acute or chronic)
• History of major surgical procedures involving the stomach potentially affectingabsorption of trial product (e.g. subtotal and total gastrectomy, sleeve gastrectomy,gastric bypass surgery)
• Subjects presently classified as being in New York Heart Association (NYHA) Class IVheart failure
• Planned coronary, carotid or peripheral artery revascularisation known on the day ofscreening
• Any of the following: myocardial infarction, stroke or hospitalisation for unstableangina or transient ischaemic attack within the past 60 days prior to screening
• Chronic or intermittent hemodialysis or peritoneal dialysis or severe renal impairment (corresponding to eGFR (glomerular filtration rate, estimated) below 30 mL/min/1.73m^2)
• History or presence of malignant neoplasms within the last 5 years (except basal andsquamous cell skin cancer and carcinoma in situ)